144 related articles for article (PubMed ID: 15540115)
41. Oncolytic herpes simplex virus type-1 therapy in a highly infiltrative animal model of human glioblastoma.
Huszthy PC; Goplen D; Thorsen F; Immervoll H; Wang J; Gutermann A; Miletic H; Bjerkvig R
Clin Cancer Res; 2008 Mar; 14(5):1571-80. PubMed ID: 18316582
[TBL] [Abstract][Full Text] [Related]
42. Use of herpes simplex virus type 1-based amplicon vector for delivery of small interfering RNA.
Sabbioni S; Callegari E; Manservigi M; Argnani R; Corallini A; Negrini M; Manservigi R
Gene Ther; 2007 Mar; 14(5):459-64. PubMed ID: 17051250
[TBL] [Abstract][Full Text] [Related]
43. [*OPCML gene transferred by recombinant lentiviruses in vitro and its inhibition to ovarian cancer cells].
Yao DS; Li L; Garson K; Vanderhyden BC
Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):333-8. PubMed ID: 16762191
[TBL] [Abstract][Full Text] [Related]
44. Comparison of HIV- and EIAV-based vectors on their efficiency in transducing murine and human hematopoietic repopulating cells.
Siapati EK; Bigger BW; Miskin J; Chipchase D; Parsley KL; Mitrophanous K; Themis M; Thrasher AJ; Bonnet D
Mol Ther; 2005 Sep; 12(3):537-46. PubMed ID: 16099415
[TBL] [Abstract][Full Text] [Related]
45. A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo.
Mairs RJ; Ross SC; McCluskey AG; Boyd M
J Nucl Med; 2007 Sep; 48(9):1519-26. PubMed ID: 17704246
[TBL] [Abstract][Full Text] [Related]
46. Cancer gene therapy using a novel secretable trimeric TRAIL.
Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW
Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699
[TBL] [Abstract][Full Text] [Related]
47. Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.
Kikuchi E; Menendez S; Ozu C; Ohori M; Cordon-Cardo C; Logg CR; Kasahara N; Bochner BH
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4511-8. PubMed ID: 17671137
[TBL] [Abstract][Full Text] [Related]
48. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
Kuppuswamy M; Spencer JF; Doronin K; Tollefson AE; Wold WS; Toth K
Gene Ther; 2005 Nov; 12(22):1608-17. PubMed ID: 16034456
[TBL] [Abstract][Full Text] [Related]
49. Specific oncolytic activity of herpesvirus saimiri in pancreatic cancer cells.
Stevenson AJ; Giles MS; Hall KT; Goodwin DJ; Calderwood MA; Markham AF; Whitehouse A
Br J Cancer; 2000 Aug; 83(3):329-32. PubMed ID: 10917547
[TBL] [Abstract][Full Text] [Related]
50. High antitumor activity using intratumoral injection of plasmid DNA with mutant-type p27Kip1 gene following in vivo electroporation.
Harada K; Supriatno ; Kawaguchi S; Onoue T; Kawashima Y; Yoshida H; Sato M
Oncol Rep; 2005 Feb; 13(2):201-6. PubMed ID: 15645112
[TBL] [Abstract][Full Text] [Related]
51. Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy.
Mitrofanova E; Unfer R; Vahanian N; Link C
Gene Ther; 2006 Jul; 13(13):1052-6. PubMed ID: 16525480
[TBL] [Abstract][Full Text] [Related]
52. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
53. The terminal repeats and latency-associated nuclear antigen of herpesvirus saimiri are essential for episomal persistence of the viral genome.
Collins CM; Medveczky MM; Lund T; Medveczky PG
J Gen Virol; 2002 Sep; 83(Pt 9):2269-2278. PubMed ID: 12185282
[TBL] [Abstract][Full Text] [Related]
54. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC).
Zietarska M; Maugard CM; Filali-Mouhim A; Alam-Fahmy M; Tonin PN; Provencher DM; Mes-Masson AM
Mol Carcinog; 2007 Oct; 46(10):872-85. PubMed ID: 17455221
[TBL] [Abstract][Full Text] [Related]
55. Potential of herpesvirus saimiri-based vectors to reprogram a somatic Ewing's sarcoma family tumor cell line.
Brown HF; Unger C; Whitehouse A
J Virol; 2013 Jun; 87(12):7127-39. PubMed ID: 23596304
[TBL] [Abstract][Full Text] [Related]
56. A novel method for viral gene delivery in solid tumors.
Wang Y; Liu S; Li CY; Yuan F
Cancer Res; 2005 Sep; 65(17):7541-5. PubMed ID: 16140915
[TBL] [Abstract][Full Text] [Related]
57. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
[TBL] [Abstract][Full Text] [Related]
58. Sustained expression of Epstein-Barr virus episomal vector mediated factor VIII in vivo following muscle electroporation.
Mei WH; Qian GX; Zhang XQ; Zhang P; Lu J
Haemophilia; 2006 May; 12(3):271-9. PubMed ID: 16643213
[TBL] [Abstract][Full Text] [Related]
59. Murine and HIV-based retroviral vectors for in vitro and in vivo gene transfer.
Alfa RW; Blesch A
Methods Mol Med; 2006; 129():241-54. PubMed ID: 17085815
[TBL] [Abstract][Full Text] [Related]
60. Treatment of pancreatic carcinoma by adenoviral mediated gene transfer of vasostatin in mice.
Li L; Yuan YZ; Lu J; Xia L; Zhu Y; Zhang YP; Qiao MM
Gut; 2006 Feb; 55(2):259-65. PubMed ID: 16287901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
